Australia : RHH Pharmacy upgrade to support Nation Leading Jack Jumper Allergy Program.
The Hodgman Liberal Governments investment of $3.7 million to redevelop the Royal Hobart Hospital Pharmacy will underpin the ongoing work of the Jack Jumper Allergy Program, which has recently played a key role in assisting Victoria to establish its own immunotherapy program.
The pharmacy is critical to the production of clinical grade jack jumper venom which is then used to provide desensitisation treatment to patients with life-threatening allergies to jack jumpers.
In 2015, the program began accepting referrals from Victoria, with 31 patients referred.
Monash Health commenced work on establishing a Victorian clinic with the Tasmanian program providing the necessary protocols and information.
The Jack Jumper Allergy Program also supplied jack jumper venom active pharmaceutical ingredient to Monash Health which is then formulated into clinical grade venom.
Four patients have now commenced immunotherapy at Monash Health.
The Tasmanian program, which has been leading research into jack jumper allergies for 16 years, currently treats more than 300 patients at both the RHH and the North West Regional Hospital.
The pharmacy upgrade will include dedicated facilities for the Jack Jumper Allergy Program to continue current production levels and expand if necessary.
As well as supporting the Jack Jumper Allergy Program, the RHH Pharmacy Department oversees the provision of medication to more than 1000 patients a day including inpatients and outpatients of the RHH and other centres.
[c] 2016 Al Bawaba (Albawaba.com) Provided by SyndiGate Media Inc. ( Syndigate.info ).
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 7, 2016|
|Previous Article:||Australia : More teachers and a focus on Education.|
|Next Article:||Australia : Leading Accelerator Program to visit Launceston.|